In our recent preclinical study using a CD276-targeted ADC (m276-SL-PBD), we observed an objective response rate of 93% in the neuroblastoma CDXs and PDXs.19 Importantly, all neuroblastoma PDXs assessed display a strong ADRN signature, so the efficacy of CD276-targeted agents, as well as other preclinical molecules, remains to be determined in MES-dominant neuroblastomas. This evidence concerns the gene CD276 and neuroblastoma.